Short answer · Medically reviewed summary · Last updated: 2026-04-07
Stiff Person Syndrome (SPS) was first described in 1956 by physicians Frederick Moersch and Henry Woltman, who initially termed the condition "stiff-man syndrome." Over the decades, our understanding has shifted from viewing it as a purely neurological or psychological ailment to recognizing it as a complex autoimmune disorder characterized by antibodies targeting the enzyme glutamic acid decarboxylase (GAD). When was Stiff Person Syndrome first identified? The history of Stiff Person Syndrome began at the Mayo Clinic in 1956. Drs.
2 people with Stiff Person Syndrome have shared their first-person experience on this question at DiseaseMaps.
What is the history of Stiff Person Syndrome?
History of Stiff Person Syndrome: when and how it was discovered, and the milestones in research since, medically reviewed.
Stiff Person Syndrome (SPS) was first described in 1956 by physicians Frederick Moersch and Henry Woltman, who initially termed the condition "stiff-man syndrome." Over the decades, our understanding has shifted from viewing it as a purely neurological or psychological ailment to recognizing it as a complex autoimmune disorder characterized by antibodies targeting the enzyme glutamic acid decarboxylase (GAD).
When was Stiff Person Syndrome first identified?
The history of Stiff Person Syndrome began at the Mayo Clinic in 1956. Drs. Frederick Moersch and Henry Woltman published a landmark paper describing 14 patients who presented with progressive muscular rigidity and painful spasms. Initially, the condition was referred to as "stiff-man syndrome," a name that persisted for many years. Early researchers were fascinated by the peculiar "wooden" posture and the intense sensitivity to external stimuli, which often triggered debilitating muscle contractions.
How has our understanding of Stiff Person Syndrome evolved?
For decades, the medical community struggled to categorize the disease, and many patients were misdiagnosed with psychiatric conditions or primary muscle disorders. A major turning point occurred in the late 1980s and 1990s when researchers identified the presence of anti-GAD antibodies in the serum of many patients. This discovery fundamentally changed the classification of Stiff Person Syndrome, moving it from a mysterious neurological curiosity to a well-defined autoimmune disease involving the central nervous system.
What were the major milestones in treatment and diagnosis?
The management of Stiff Person Syndrome has evolved from basic symptomatic relief to targeted immunomodulatory therapies. Key milestones in the clinical history of the condition include:
- 1960s–1970s: The introduction of diazepam (Valium) as the first effective treatment for muscle rigidity, which remains a cornerstone of care today.
- 1990s: The development of diagnostic blood tests to detect anti-GAD65 antibodies, allowing for earlier and more accurate identification.
- 2000s–Present: The integration of intravenous immunoglobulin (IVIG) and plasma exchange (plasmapheresis) as standard immunotherapies to address the underlying autoimmune activity.
- Emerging research: Ongoing clinical trials investigating B-cell depletion therapies, such as rituximab, represent the current frontier of treatment.
How has patient advocacy changed the landscape?
Historically, patients with Stiff Person Syndrome faced significant isolation due to the rarity of the condition and the lack of public awareness. The formation of patient-led organizations has been vital in shifting the narrative. Today, platforms like DiseaseMaps.org, which hosts 179 members currently living with Stiff Person Syndrome, have empowered individuals to share their clinical journeys, pool anecdotal evidence, and drive the research agenda. This collective voice has been instrumental in securing more funding for clinical trials and fostering connections between patients and top-tier neurological specialists.
How does modern technology impact our understanding?
Technological advancements in genomics and neuro-immunology have refined our perspective on Stiff Person Syndrome. High-throughput antibody screening and sophisticated neuroimaging have allowed physicians to differentiate between variants of the disease, such as stiff-limb syndrome or paraneoplastic forms. While we do not yet have a cure, modern diagnostic tools allow us to monitor the disease activity more precisely than ever before, ensuring that patients receive timely interventions to preserve their quality of life.
Next steps
- Consult with a neurologist specializing in neuro-immunology to discuss the latest antibody testing and treatment protocols.
- Connect with the 179 members in the DiseaseMaps.org community to share experiences and coping strategies.
- Monitor the NIH GARD website for updates on ongoing clinical trials and research initiatives.
- Keep a detailed symptom diary to help your care team assess the effectiveness of your current treatment regimen.
Medical disclaimer: This content is for informational purposes only and does not constitute professional medical advice, diagnosis, or treatment; always seek the advice of your physician with any questions regarding a medical condition.
References
- NIH Genetic and Rare Diseases Information Center (GARD) - Stiff Person Syndrome.
- Orphanet: The portal for rare diseases and orphan drugs.
- Moersch, F. P., & Woltman, H. W. (1956). Progressive fluctuating muscular rigidity and spasm ("stiff-man" syndrome). Mayo Clinic Proceedings.
- OMIM (Online Mendelian Inheritance in Man) - Database entry for Stiff Person Syndrome.
At Mayo Clinic, physicians Dr. Frederick Moersch (1889-1975) and Dr. Henry Woltman (1889-1964) collected case studies of patients who presented with progressive, symmetrical rigidity of axial and proximal limb muscles.
In 1956, they presented a paper covering fourteen patients collected over thirty-two years. Ten patients were men and four were women. The average age of onset was forty-one years. All were progressive and responded poorly to treatments. Four had diabetes mellitus. Two had epilepsy: one with grand-mal seizures and one with petit-mal seizures. They concluded, because of the fluctuating nature of the symptoms and the association with diabetes, that a metabolic basis for the disease should be considered.
The disease was initially named Moersch-Woltman syndrome in their honor.
Posted Dec 25, 2021 by Pathdoc 2500
There is an infantile form that affects a lower limb (stiff leg)
And the most common, which is that of a patient who begins to notice loss of elasticity in the sport or work activity. Pain and/or stiffness as he tries to overcome a effort. Spasms provoked by the slightest contact, sound and emotional experiences, The patient is blocked in the presence of a well-known friend or close friend, Trouble down the curb of a street and cross it. The patient tends to cross between the cars instead of the step enabled with traffic lights, to avoid being obsrvado by the drivers. The falls are mainly due to the inability to stay on a foot, The falls are accompanied by a noise glottic and in hyperextension. Are frequent falls with stitches in the chin.
Posted Sep 18, 2017 by Fernando Vela Vallejo 3250
